Dr. Barrangou is the T. R. Klaenhammer Distinguished Professor at North Carolina State University. He is focusing on the characterization of CRISPR-Cas systems and their applications in bacteria. Dr. Barrangou spent 9 years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. He has received several international awards, and was elected into the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Inventors. Dr. Barrangou is a co-founder of Intellia Therapeutics, Locus Biosciences, TreeCo, Ancilia Biosciences and CRISPR Biotechnologies, and the Editor in Chief of the CRISPR Journal. He earned a BS in Biological Sciences from Rene Descartes University, France, an MS in Biological Engineering from the University of Technology in Compiegne, France, an MS in Food Science from NC State, a PhD in Genomics from NC State, and an MBA from the University of Wisconsin-Madison.